MOTS-c and Exercise: Human Evidence vs. Animal Performance Claims

Evidence note: Research records and FDA status were rechecked on August 29, 2026. Medical review of this revision is pending; the historical review date has not been overwritten. FDA, trial registries, authors, and institutions do not endorse HealthRX.com or this page.

Start by Separating Two Questions

MOTS-c and exercise are linked in the literature, but the direction of the question changes the evidence:

1. Does exercise change endogenous MOTS-c? Small human and animal studies say it can, with inconsistent patterns across methods and populations.
2. Does administering MOTS-c improve exercise performance in people? Mouse experiments support the hypothesis; published human performance evidence has not yet established the claim.

Marketing often blends those questions into “MOTS-c is an exercise mimetic.” That phrase compresses a plausible biological relationship into a treatment conclusion the human evidence does not support.

Evidence Map: From Exercise Response to Product Claim

This map blocks a common evidence error: an endogenous response to exercise does not prove that administering the molecule creates the same response.

What the Mouse Performance Studies Actually Tested

The 2021 Nature Communications study combined cellular work, young and aged mouse experiments, and human observational measurements. In mice, administered MOTS-c improved treadmill outcomes across ages and changed muscle metabolism and stress-response pathways 3. The study is important because it links the peptide to physical capacity rather than only glucose measures.

It still does not answer whether a person runs farther, recovers faster, gains muscle, or benefits when MOTS-c is added to training. Mouse doses expressed per kilogram cannot be linearly converted into a human pre-workout protocol, and treadmill performance in a controlled mouse experiment is not a surrogate for long-term human training benefit.

A 2022 rodent study further found that several weeks of voluntary running increased MOTS-c protein in specific muscles and that a single experimental MOTS-c dose improved acute running time by 12% and distance by 15% in untrained mice 4. Those exact percentages belong to that mouse experiment—not to athletes or patients.

What the Human Exercise Studies Mean

Human research has generally measured naturally occurring MOTS-c around exercise rather than administering a MOTS-c product and testing performance.

In one acute-exercise study, endurance and resistance sessions produced different circulating mitochondrial-peptide responses 1. Ferdinand von Walden and colleagues reported that “Plasma levels of MDPs were not correlated to fitness outcomes [V̇O2max, leg strength, or muscle mitochondrial (mt) DNA copy number].” 1 That sentence is useful precisely because the researchers measured endogenous mitochondrial-derived peptides; they did not administer MOTS-c or test whether a product improved performance. In a separate intervention among breast-cancer survivors, changes and associations differed by ethnicity and outcome 2. A field review concluded that tissue and circulating responses remain inconsistent and may depend on exercise mode, duration, intensity, and participant characteristics 6.

These findings are scientifically useful because they identify measurement questions for a human trial. They are not evidence for a consumer injection schedule.

What the 2026 Trial Will—and Will Not—Resolve

ClinicalTrials.gov lists NCT07505745 as a recruiting, randomized, placebo-controlled Phase 2a study in 120 adults with prediabetes and overweight or obesity 5. Its listed primary outcomes are change in an oral-glucose-tolerance-test-derived insulin-sensitivity index and treatment-emergent adverse events. Secondary outcomes include glucose measures and immunogenicity.

No results are posted, and the primary completion is estimated for 2027. Registration proves that a protocol exists; it does not prove benefit. Even a positive metabolic result would not automatically establish improved speed, endurance, strength, recovery, or sports performance.

FDA and Product-Quality Context

MOTS-c is not an FDA-approved drug. FDA's compounding safety-risk page describes potential immunogenicity and peptide-impurity or active-ingredient characterization concerns 7. MOTS-c-related bulk substances were also considered at the July 2026 Pharmacy Compounding Advisory Committee meeting 8.

That regulatory context does not erase the research. It changes what can be claimed about a product. A vial sold online cannot be assumed to match experimental material in sequence identity, potency, sterility, aggregation, storage, or impurities.

A Training-Claim Record That Avoids Self-Deception

Before accepting a MOTS-c performance claim, record:

Exercise itself has extensive human evidence across metabolic, cardiovascular, bone, and mental-health outcomes. MOTS-c should not displace a suitable training plan while its added human value remains unresolved.

For related decisions, compare the peptide evidence-and-product ladder, our MOTS-c rare-risk evidence review, and the KPV human-versus-preclinical evidence replay.